Effect of buprenorphine dose on treatment outcome

Journal of Addictive Diseases

Volumn 31, Issue 1, 2012, Pages 8-18

  Fareed, Ayman ^a   Vayalapalli, Sreedevi ^a   Casarella, Jennifer ^a   Drexler, Karen ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Buprenorphine; Dose; Treatment outcome

Indexed keywords

BUPRENORPHINE; ILLICIT DRUG; OPIATE;

ARTICLE; DOSE RESPONSE; HUMAN; MAINTENANCE THERAPY; META ANALYSIS; OPIATE ADDICTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; URINALYSIS;

BUPRENORPHINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; HUMANS; MEDICATION ADHERENCE; NARCOTIC ANTAGONISTS; OPIOID-RELATED DISORDERS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84858147235     PISSN: 10550887     EISSN: 15450848     Source Type: Journal    
DOI: 10.1080/10550887.2011.642758     Document Type: Article

References (56)

1. Cowan A. Buprenorphine: the basic pharmacology revisited. J Addict Med 2007; 1(2):68-72.
2. Gerra G, Fantoma A, Zaimovic A. Naltrexone and buprenorphine combination in the treatment of opioid dependence. J Psychopharmacol 2006; 20(6):806-14. (Pubitemid 44622745)
3. Jones HJ, Kaltenbach K, Heil H, et al. Neonatal abstinence syndrome after methadone or buprenorphine exposure. N Engl J Med 2010; 363:2320-31.
4. Amass L, Ling W, Freese TE, et al. Bringing buprenorphine-naloxone detoxification to community treatment providers: the NIDA Clinical Trials Network field experience. Am J Addict 2004; 13(Suppl 1):S42-66. (Pubitemid 38585690)
5. Amass L, Kamien JB, Mikulich SK. Efficacy of daily and alternate-day dosing regimens with the combination buprenorphinenaloxone tablet. Drug Alcohol Depend 2000; 58:143-52.
6. Caldiero R, Parran T Jr, Adelman C, Piche B. Inpatient initiation of buprenorphine maintenance vs. detoxification: can retention of opioid-dependent patients in outpatient counseling be improved? Am J Addict 2006; 15:1-7. (Pubitemid 43207183)
7. Johnson RE, Eissenberg T, Stitzer MI, et al. A placebo controlled clinical trial of buprenorphine as a treatment for opioid dependence. Drug Alcohol Depend 1995; 40:17-25.
8. White J, Bell J, Saunders J, et al. Open-label dose-finding trial of buprenorphine implants (Probuphine) for treatment of heroin dependence. Drug Alcohol Depend 2009; 103:37-43.
9. Eder H, Fischer G, Gombas W, Jagsch R, Stuhlinger G, Kasper S. Comparison of buprenorphine and methadone maintenance in opiate addicts. Eur Addict Res 1998; 4(Suppl 1):3-7. (Pubitemid 28478987)
10. Greenwald M, Johanson C, Schuster C. Opioid reinforcement in heroindependent volunteers during outpatient buprenorphine maintenance. Drug Alcohol Depend 1999; 56:191-203. (Pubitemid 29401888)
11. Ling W, Wesson DR, Charuvastra C, Klett CJ. A controlled trial comparing buprenorphine and methadone maintenance in opioid dependence. Arch Gen Psychiatry 1996; 53(5):401-7. (Pubitemid 26149228)
12. Mattick RP, Ali R, White JM, O'Brien S, Wolk S, Danz C. Buprenorphine versus methadone maintenance therapy: a randomized double-blind trial with 405 opioid-dependent patients. Addiction 2003; 98(4):441-52. (Pubitemid 36458126)
13. Comer S, Collins E, Fischman. Buprenorphine sublingual tablets: effects on IV heroin self-administration by humans. Psychopharmacology 2001; 154:28-37. (Pubitemid 32186512)
14. Greenwald M, Schuh K, Hopper J, Schuster C, Johanson C. Effects of buprenorphine sublingual tablet maintenance on opioid drug-seeking behavior by humans. Psychopharmacology 2002; 160:344-52. (Pubitemid 34253276)
15. Kakko J, Svanborg KD, Kreek MJ, Heilig M. 1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomised, placebo-controlled trial. Lancet 2003; 361(9358):662-8. (Pubitemid 36246548)
16. Ling W, Charuvastra C, Collins JF, et al. Buprenorphine maintenance treatment of opiate dependence: a multicenter,randomized clinical trial. Addiction 1998; 93:475-86. (Pubitemid 28188067)
17. Fudala PJ, Bridge TP, Herbert S, et al. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. N Engl J Med 2003; 349(10):949-58. (Pubitemid 37064768)
18. Johnson RE, Chutuape MA, Strain EC, Walsh SL, Stitzer ML, Bigelow GE. A comparison of levomethadyl acetate, buprenorphine, and METH for opioid dependence. N Engl J Med 2000; 343:1290-7.
19. Kakko J, Grönbladh L, Svanborg KD, et al. A stepped care strategy using buprenorphine and methadone versus conventional methadone maintenance in heroin dependence: a randomized controlled trial. Am J Psychiatry 2007; 164(5):797-803. (Pubitemid 46808535)
20. Reckitt Benckiser. SUBOXONE treatment walk-through. http://suboxone.com/ patients/about suboxone tablets.aspx. (accessed April 23, 2007).
21. Chakrabarti A, Woody GE, Griffin ML, Subramaniam G, Weiss RD. Predictors of buprenorphine-naloxone dosing in a 12- week treatment trial for opioid-dependent youth: secondary analyses from a NIDA Clinical Trials Network study. Drug Alcohol Depend 2010; 107(2-3):253-6.
22. Dahan A, Yassen A, Romberg R, et al. Buprenorphine induces ceiling in respiratory depression but not in analgesia. Br J Anaesth 2006; 96:627-62.
23. Liguori A, Morse WH, Bergman J. Respiratory effects of opioid full and partial agonists in rhesus monkeys. J Pharmacol Exp Ther 1996; 277:462-72. (Pubitemid 27169093)
24. Walsh SL, Preston KL, Stitzer ML, et al. Clinical pharmacology of buprenorphine: ceiling effects at high doses. Clin Pharmacol Ther 1994; 55:569-80. (Pubitemid 24192243)
25. Häkkinen M, Launiainen T, Vuori E, Ojanperä I. Benzodiazepines and alcohol are associated with cases of fatal buprenorphine poisoning. Eur J Clin Pharmacol 2011 Sept 17 [Epub ahead of print].
26. Ferrant O, Papin F, Clin B, et al. Fatal poisoning due to snorting buprenorphine and alcohol consumption. Forensic Sci Int 2011; 204(1-3):e8-11.
27. Jadad AR; Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17(1):1-12. doi:10.1016/0197-2456(95)00134-4 (Pubitemid 26120810)
28. Bell JR, Butler B, Lawrance A, Batey R, Salmelainen P. Comparing overdose mortality associated with methadone and buprenorphine treatment. Drug Alcohol Depend 2009; 104(1-2):73-7.
29. Bell J, Trinh L, Butler B, Randall D, Rubin G. Comparing retention in treatment and mortality in people after initial entry to methadone and buprenorphine treatment. Addiction 2009; 104(7):1193-200.
30. Altice FL, Bruce RD, Lucas GM, et al. BHIVES Collaborative. HIV treatment outcomes among HIV-infected, opioiddependent patients receiving buprenorphine/ naloxone treatment within HIV clinical care settings: results from a multisite study. J Acquir Immune Defic Syndr 2011; 56(Suppl 1):S22-32.
31. Bilal S, Menares J, De La Selle P, Toufik A, Perdrieux Y. Effect of maintenance treatments on social life. A study with general practitioners [article in French]. Ann Med Interne (Paris) 2003; 154(Spec No 2):S6-14.
32. Korthuis PT, Fiellin DA, Fu R, et al. BHIVES Collaborative. Improving adherence toHIV quality of care indicators in persons with opioid dependence: the role of buprenorphine. J Acquir Immune Defic Syndr 2011; 56(Suppl 1):S83-90.
33. Parran TV, Adelman CA, Merkin B, et al. Long-term outcomes of officebased buprenorphine/naloxone maintenance therapy. Drug Alcohol Depend 2010; 106(1):56-60
34. Vergara-Rodriguez P, Tozzi MJ, Botsko M, et al. BHIVES Collaborative. Hepatic safety and lack of antiretroviral interactions with buprenorphine/ naloxone in HIV-infected opioid-dependent patients. J Acquir Immune Defic Syndr 2011; 56(Suppl 1): S62-7.
35. Korthuis PT, Tozzi MJ, Nandi V, et al. BHIVES Collaborative. Improved quality of life for opioid-dependent patients receiving buprenorphine treatment in HIV clinics. J Acquir Immune Defic Syndr 2011; 56(Suppl 1): S39-45.
36. Auriacombe M, Fatseas M, Dubernet J, Daulouede JP, Tignol J. French field experience with buprenorphine. Am J Addict 2004; 13(Suppl 1):17-28.
37. Jenkinson RA, ClarkNC, Fry CL,DobbinM. Buprenorphine diversion and injection in Melbourne, Australia: an emerging issue? Addiction 2005; 100:197-205. (Pubitemid 40255377)
38. Mattick RP, Kimber J, Breen C, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev 2008; (2):CD002207.
39. Kosten TR, Schottenfeld R, Ziedonis D, Falcioni J. Buprenorphine versus methadone maintenance for opioid dependence. J Nerv Ment Dis. 1993; 181:358-64. (Pubitemid 24259606)
40. Schottenfeld RS, Pakes JR, Oliveto A, Ziedonis D, Kosten TR. Buprenorphine vs methadone maintenance treatment for concurrent opioid dependence and cocaine abuse. Arch Gen Psychiatry 1997; 54(8):713-20. (Pubitemid 27344098)
41. Uehlinger C, Deglon J-J, Livoti S, Petitjean S, Waldvogel D, Ladewig D. Comparison of buprenorphine and methadone in the treatment of opioid dependence: Swiss multicentre trial. Eur Addict Res 1998; 4:13-8. (Pubitemid 28478989)
42. Crits-Christoph P, Siqueland L, Blaine J, et al. Psychosocial treatments for cocaine dependence: National Institute on Drug Abuse Collaborative Cocaine Treatment Study. Arch Gen Psychiatry 1999; 56:493-502. (Pubitemid 29304640)
43. Kosten T, Oliveto A, Feingold A, et al. Desipramine and contingency management for cocaine and opiate dependence in buprenorphine maintained patients. Drug Alcohol Depend 2003; 70:315-25. (Pubitemid 36577343)
44. Schottenfeld RS, Chawarski MC, Pakes JR, et al. Methadone versus buprenorphine with contingency management or performance feedback for cocaine and opioid dependence. Am J Psychiatry 2005; 162:340-9. (Pubitemid 40216216)
45. Simpson DD, Joe GW, Fletcher BW, et al. A national evaluation of treatment outcomes for cocaine dependence. Arch Gen Psychiatry 1999; 56:507-14. (Pubitemid 29304643)
46. Springer SA, Chen S, Altice FL. Improved HIV and substance abuse treatment outcomes for released HIV-infected prisoners: the impact of buprenorphine treatment. J Urban Health 2010; 87(4):592-602.
47. Sullivan LE, Barry D, Moore BA, et al. A trial of integrated buprenorphine/naloxone and HIV clinical care. Clin Infect Dis 2006; 43(Suppl 4):S184-90. (Pubitemid 44901886)
48. Strain EC, Stitzer ML, Liebson IA, Bigelow GE. Buprenorphine versus methadone in the treatment of opioid dependence: selfreports, urinalysis, and addiction severity index. J Clin Psychopharmacol 1996; 16(1):58-67.
49. Woody GE, Poole SA, Subramaniam G, et al. Extended vs short-term buprenorphine-naloxone for treatment of opioid-addicted youth: a randomized trial. JAMA 2008; 300(17):2003-11.
50. Ahmadi J. Methadone versus buprenorphine maintenance for the treatment of heroin-dependent outpatients. J Subst Abuse Treat 2003; 24(3):217-20. (Pubitemid 37297338)
51. Amass L, Kamien JB, Mikulich SK. Thriceweekly supervised dosing with the combination buprenorphine-naloxone tablet is preferred to daily supervised dosing by opioid-dependent humans. Drug Alcohol Depend 2001; 61(2):173-81. (Pubitemid 32008531)
52. Fiellin DA, Pantalon MV, Chawarski MC, et al. Counseling plus buprenorphinenaloxone maintenance therapy for opioid dependence. N Engl J Med 2006; 355(4):365-74. (Pubitemid 44127539)
53. Lucas GM, Chaudhry A, Hsu J, et al. Clinicbased treatment of opioid-dependent HIVinfected patients versus referral to an opioid treatment program: a randomized trial. Ann Intern Med 2010; 152(11): 704-11.
54. Marsch LA, Bickel WK, Badger GJ, Jacobs EA. Buprenorphine treatment for opioid dependence: the relative efficacy of daily, twice and thrice weekly dosing. Drug Alcohol Depend 2005; 77(2): 195-204. (Pubitemid 40128198)
55. Montoya ID, Gorelick DA, Preston KL, et al. Randomized trial of buprenorphine for treatment of concurrent opiate and cocaine dependence. Clin Pharmacol Ther 2004; 75(1):34-48.
56. Schottenfeld RS, Pakes J, O'Connor P, ChawarskiM,Oliveto A, Kosten TR. Thriceweekly versus daily buprenorphine maintenance. Biol Psychiatr. 2000; 47(12): 1072-9. (Pubitemid 30336216)